{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:27Z","timestamp":1793317587040,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS601"],"award-info":[{"award-number":["21153MFDS601"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00331719 and RS-2024-00345981"],"award-info":[{"award-number":["RS-2024-00331719 and RS-2024-00345981"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28172-6","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:19:58Z","timestamp":1766582398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of bisphosphonates after denosumab discontinuation and treatment effect heterogeneity using causal machine learning"],"prefix":"10.1038","volume":"15","author":[{"given":"Miryoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-6607","authenticated-orcid":false,"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"28172_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge, R. et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J. Bone Miner. Res. 22, 465\u2013475 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"28172_CR2","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00198-017-3985-4","volume":"28","author":"N Mohd-Tahir","year":"2017","unstructured":"Mohd-Tahir, N. & Li, S. Economic burden of osteoporosis-related hip fracture in Asia: A systematic review. Osteoporos. Int. 28, 2035\u20132044 (2017).","journal-title":"Osteoporos. Int."},{"key":"28172_CR3","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/jama.2019.5453","volume":"321","author":"SD Berry","year":"2019","unstructured":"Berry, S. D., Kiel, D. P. & Col\u00f3n-Emeric, C. Hip fractures in older adults in 2019. JAMA 321, 2231\u20132232 (2019).","journal-title":"JAMA"},{"key":"28172_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc, D. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301, 513\u2013521 (2009).","journal-title":"JAMA"},{"key":"28172_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/jamainternmed.2021.2617","volume":"181","author":"CJ Crandall","year":"2021","unstructured":"Crandall, C. J. et al. Risk of subsequent fractures in postmenopausal women after nontraumatic vs traumatic fractures. JAMA Intern. Med. 181, 1055\u20131063 (2021).","journal-title":"JAMA Intern. Med."},{"key":"28172_CR6","doi-asserted-by":"publisher","first-page":"115286","DOI":"10.1016\/j.bone.2020.115286","volume":"134","author":"E S\u00f6reskog","year":"2020","unstructured":"S\u00f6reskog, E. et al. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone 134, 115286 (2020).","journal-title":"Bone"},{"key":"28172_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston, J. et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos. 12, 1\u201324 (2017).","journal-title":"Arch. Osteoporos."},{"key":"28172_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem, A. et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: A living clinical guideline from the American college of physicians. Ann. Intern. Med. 176, 224\u2013238 (2023).","journal-title":"Ann. Intern. Med."},{"key":"28172_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron, R., Ferrari, S. & Russell, R. G. G. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 48, 677\u2013692 (2011).","journal-title":"Bone"},{"key":"28172_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972\u2013980 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28172_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings, S. R. et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190\u2013198 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"28172_CR12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis, A. D., Papapoulos, S. E., Polyzos, S. A., Appelman-Dijkstra, N. M. & Makras, P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J. Bone Miner. Res. 34, 2220\u20132228 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"28172_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn, T. et al. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study. Osteoporos. Int. 34, 573\u2013584 (2023).","journal-title":"Osteoporos. Int."},{"key":"28172_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi, G. et al. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur. J. Endocrinol. 185, 387\u2013396 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"28172_CR15","first-page":"1717","volume":"36","author":"Burckhardt, P., Faouzi, M., Buclin, T., Lamy, O. & Group, S. D. S","year":"2021","unstructured":"Burckhardt, P., Faouzi, M., Buclin, T., Lamy, O. & Group, S. D. S. Fractures after denosumab discontinuation: A retrospective study of 797 cases. J. Bone Miner. Res. 36, 1717\u20131728 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"28172_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/00949655.2014.929131","volume":"85","author":"M Lang","year":"2015","unstructured":"Lang, M. et al. Automatic model selection for high-dimensional survival analysis. J. Stat. Comput. Simul. 85, 62\u201376 (2015).","journal-title":"J. Stat. Comput. Simul."},{"key":"28172_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3214306","volume":"51","author":"P Wang","year":"2019","unstructured":"Wang, P., Li, Y. & Reddy, C. K. Machine learning for survival analysis: A survey. ACM Comput. Surv. (CSUR) 51, 1\u201336 (2019).","journal-title":"ACM Comput. Surv. (CSUR)"},{"key":"28172_CR18","doi-asserted-by":"crossref","unstructured":"Athey, S., Tibshirani, J. & Wager, S. Generalized random forests. (2019).","DOI":"10.1214\/18-AOS1709"},{"key":"28172_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","volume":"85","author":"Y Cui","year":"2023","unstructured":"Cui, Y., Kosorok, M. R., Sverdrup, E., Wager, S. & Zhu, R. Estimating heterogeneous treatment effects with right-censored data via causal survival forests. J. R. Stat. Soc. Ser. B Stat Methodol. 85, 179\u2013211 (2023).","journal-title":"J. R. Stat. Soc. Ser. B Stat Methodol."},{"key":"28172_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00198-014-2875-2","volume":"26","author":"L Hansen","year":"2015","unstructured":"Hansen, L. et al. Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos. Int. 26, 513\u2013519 (2015).","journal-title":"Osteoporos. Int."},{"key":"28172_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-020-00852-y","volume":"15","author":"Y-B Shim","year":"2020","unstructured":"Shim, Y.-B. et al. Incidence and risk factors of subsequent osteoporotic fracture: A nationwide cohort study in South Korea. Arch. Osteoporos. 15, 1\u20137 (2020).","journal-title":"Arch. Osteoporos."},{"key":"28172_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/EDE.0000000000000409","volume":"27","author":"CJ Howe","year":"2016","unstructured":"Howe, C. J., Cole, S. R., Lau, B., Napravnik, S. & Eron, J. J. Jr. Selection bias due to loss to follow up in cohort studies. Epidemiology 27, 91\u201397 (2016).","journal-title":"Epidemiology"},{"key":"28172_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised freedom trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"28172_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari, S. & Langdahl, B. Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat. Rev. Rheumatol. 19, 307\u2013317 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"28172_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00198-019-04852-8","volume":"30","author":"J Banefelt","year":"2019","unstructured":"Banefelt, J. et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos. Int. 30, 601\u2013609 (2019).","journal-title":"Osteoporos. Int."},{"key":"28172_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00198-020-05602-x","volume":"32","author":"S-B Lee","year":"2021","unstructured":"Lee, S.-B. et al. Association between mortality risk and the number, location, and sequence of subsequent fractures in the elderly. Osteoporos. Int. 32, 233\u2013241 (2021).","journal-title":"Osteoporos. Int."},{"key":"28172_CR27","first-page":"461","volume":"23","author":"J Weaver","year":"2017","unstructured":"Weaver, J., Sajjan, S., Lewiecki, E. M., Harris, S. T. & Marvos, P. Prevalence and cost of subsequent fractures among US patients with an incident fracture. J. Manag. Care Spec. Pharm. 23, 461\u2013471 (2017).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"28172_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss, S. et al. Graphical depiction of longitudinal study designs in health care databases. Ann. Intern. Med. 170, 398\u2013406 (2019).","journal-title":"Ann. Intern. Med."},{"key":"28172_CR29","doi-asserted-by":"publisher","first-page":"W-163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke, J. P. et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Ann. Intern. Med. 147, W-163-W\u2212194 (2007).","journal-title":"Ann. Intern. Med."},{"key":"28172_CR30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"J-A Kim","year":"2017","unstructured":"Kim, J.-A., Yoon, S., Kim, L.-Y. & Kim, D.-S. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: Strengths, limitations, applications, and strategies for optimal use of HIRA data. J. Korean Med. Sci. 32, 718\u2013728 (2017).","journal-title":"J. Korean Med. Sci."},{"key":"28172_CR31","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/jbmr.3807","volume":"34","author":"NC Wright","year":"2019","unstructured":"Wright, N. C. et al. The design and validation of a new algorithm to identify incident fractures in administrative claims data. J. Bone Miner. Res. 34, 1798\u20131807 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"28172_CR32","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","volume":"33","author":"J Ha","year":"2022","unstructured":"Ha, J. et al. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporos. Int. 33, 1591\u20131599 (2022).","journal-title":"Osteoporos. Int."},{"key":"28172_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.37737\/ace.22005","volume":"4","author":"M Iwagami","year":"2022","unstructured":"Iwagami, M. & Shinozaki, T. Introduction to matching in case-control and cohort studies. Ann. Clin. Epidemiol. 4, 33\u201340 (2022).","journal-title":"Ann. Clin. Epidemiol."},{"key":"28172_CR34","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"JW Song","year":"2010","unstructured":"Song, J. W. & Chung, K. C. Observational studies: Cohort and case-control studies. Plast. Reconstr. Surg. 126, 2234 (2010).","journal-title":"Plast. Reconstr. Surg."},{"key":"28172_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk, M. J. et al. Doubly robust estimation of causal effects. Am. J. Epidemiol. 173, 761\u2013767 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"28172_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs, A. & Sculpher, M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13, 397\u2013409 (1998).","journal-title":"Pharmacoeconomics"},{"key":"28172_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ectj\/utaa027","volume":"24","author":"V Semenova","year":"2021","unstructured":"Semenova, V. & Chernozhukov, V. Debiased machine learning of conditional average treatment effects and other causal functions. Economet. J. 24, 264\u2013289 (2021).","journal-title":"Economet. J."},{"key":"28172_CR38","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.aap.2021.106507","volume":"165","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Li, H. & Ren, G. Estimating heterogeneous treatment effects in road safety analysis using generalized random forests. Accid. Anal. Prev. 165, 106507 (2022).","journal-title":"Accid. Anal. Prev."},{"key":"28172_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-8-12","volume":"8","author":"B Li","year":"2008","unstructured":"Li, B., Evans, D., Faris, P., Dean, S. & Quan, H. Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases. BMC Health Serv. Res. 8, 1\u20137 (2008).","journal-title":"BMC Health Serv. Res."},{"key":"28172_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-11-83","volume":"11","author":"SK Thygesen","year":"2011","unstructured":"Thygesen, S. K., Christiansen, C. F., Christensen, S., Lash, T. L. & S\u00f8rensen, H. T. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National registry of patients. BMC Med. Res. Methodol. 11, 1\u20136 (2011).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28172-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:31:12Z","timestamp":1777113072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28172-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28172"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28172-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44533"}}